Tag: <span>divestments</span>

From the Publisher: Best Corporate Practices for the Biotech Industry

There are some encouraging signs concerning the economy. We’ll know that things are improving when the big firms start to spin off companies. And the best deals will be those in which the new owners are the people who are closest to the products and technologies. As part of the deal, the divesting firm could retain certain rights or options for technologies, manufacturing, and marketing. They could also retain a certain amount of ownership in what would now be small innovative firms with people devoted to the technologies, and they could lease unused facilities to these firms instead of giving them away to people who would tear them down. And still better, would be if they returned to the very successful model of providing milestone payments when critical development goals were met…

Read MoreFrom the Publisher: Best Corporate Practices for the Biotech Industry

Biologics Production

biologics biopharmaceuticals biotech industry divestments licensing new biotechnologies spin-offs

From the Publisher: Regulations, Freedoms, and Money

First, I’m still dying to learn what the regulations are that are keeping American businesses from expanding their operations and hiring people. We keep hearing that the government has to illuminate regulations that are killing jobs, but I just can’t determine what these are. Surely the biopharmaceutical industry isn’t suggesting that it regulate itself while asking the government to protect it from litigation if something goes wrong. And I can’t believe that workplace safety or child labor laws must be abolished. So in this regard, I’ll just have to keep searching until things make sense, or I find they were never meant to…

Read MoreFrom the Publisher: Regulations, Freedoms, and Money

Biologics Production

biologics biopharmaceuticals biotech industry biotech workforce corporate structure divestments grow the market r&d research and development